Point Therapeutics Announces Time Change for January 31, 2006 Webcast; Webcast on Phase 3 NSCLC Program and Clinical Update Move
January 26 2006 - 8:15AM
Business Wire
Point Therapeutics, Inc. (NASDAQ:POTP) announced today that it has
changed the start time for its live webcast on Tuesday, January 31
to 8:30 AM EST. The webcast may be accessed by visiting
www.pther.com. About Point Therapeutics, Inc.: Point is developing
a family of dipeptidyl peptidase (DPP) inhibitors for use in
cancer, type 2 diabetes and as vaccine adjuvants. The Company is
currently studying its lead product candidate, talabostat, in a
Phase 3 trial in metastatic NSCLC. Additionally, talabostat is
being evaluated in several Phase 2 trials; including, as a
single-agent in metastatic melanoma, in combination with cisplatin
in metastatic melanoma, in combination with rituximab in advanced
chronic lymphocytic leukemia, and in combination with gemcitabine
in metastatic pancreatic cancer. Point's portfolio also includes
two other DPP inhibitors in preclinical development--PT-630 for
type 2 diabetes, and PT-510 as a vaccine adjuvant. Certain
statements contained herein are not strictly historical and are
"forward looking" statements as defined in the Private Securities
Litigation Reform Act of 1995. This information includes statements
with respect to the company's clinical development programs, the
timing of initiation and completion of its clinical trials, and the
potential of talabostat to become an important treatment for
chronic lymphocytic leukemia cancer. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believes," "feels," "expects," "may," "will," "should," "seeks,"
"plans," "schedule to," "anticipates" or "intends" or the negative
of those terms, or other variations of those terms of comparable
language, or by discussions of strategy or intentions. A number of
important factors could cause actual results to differ materially
from those projected or suggested in the forward looking statement,
including the risk factors described in Point's quarterly report on
Form 10-Q for the quarter ended September 30, 2005 and from time to
time in Point's periodic and other reports filed with the
Securities and Exchange Commission.
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Point Therapeutics (MM) (NASDAQ:POTP)
Historical Stock Chart
From Oct 2023 to Oct 2024